Capricor’s Lead Duchenne Therapy Hits FDA Regulatory Roadblock

All NewsJuly 11, 2025

FDA rejected Capricor’s BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent